They are still collecting data on the effects but according to the posts here there are few if any side effects for a person who is relatively healthy apary from having HCV.
I experienced some digestive upsets,insomnia and headaches, irritability, and a bit of a rash but most of my real discomfort was a result of extra hepatic manifestations due to HCV and cirrhosis.
Most people feel irritable on the ribavirin but again the degree of 'riba rage' depends on the individual. My Dr. told me that almost all the people in my study complained of some side effects but that overall (nationwide) the reports were that sx were minimal.
Of course compared to SOC, it is a cakewalk.
All the best :)
My husband is on a combo which includes Riba and Abbott333, Abt450 and Abt267, along with Ritonivir, and I noticed his HGB has dropped a point, although he is not anemic (less then 10) yet. He is a bit dizzy and sometimes a bit nauseous, and irritable, but the good news is, these treatments are only 12 weeks.
my fam.doc just stated today that to expect side effects probably not as bad as interferon but not to think this as a wonderdrug til all research comes out.he was kind of avoiding my question on this manner today,i had asked @last appt.to study sof/riba combo.he's still very negative towards this treatment cause he said it really gets ppl.'s hopes up.but i am like you-i want to know more.his experience is 12 years at VA hospital workin w/ HCV pts.
i would like to know what research is being done w/ high iron pts.i cannot find nothing at all.
What genotype are you?
If you are type 1 you may want to wait for the sofosbuvir/ gs-5885 (or other NS5A) combo.
I am a genotype 2b so I am looking at the sofo/riba combo without interferon due in 6 months or so
Side effects from sofosbuvir and ribavirin treatment are listed in the top line results of the clinical trials.
"In FISSION (Genotype 2/3 treatment-naïve), just 1% of patients receiving 12 weeks of sofosbuvir plus ribavirin discontinued therapy. However, a higher rate — 11% — of patients who received 24 weeks of peginterferon plus ribavirin stopped treatment."
"In the second study, known as the FUSION trial, patients who had not had a response to prior interferon therapy received sofosbuvir and ribavirin for 12 or 16 weeks. The most common adverse events were again headache, fatigue, nausea, and insomnia, but the overall discontinuation rate was low at 1% to 2%.